GALAXI-2 and GALAXI-3 published showing the efficacy of IL-23 inhibitor, Guselkumab in a 48 week study in adults with moderately to severely active Crohn's disease. https://t.co/pWolec25cX https://t.co/e2fdcMxEro
Links:
Efficacy and safety of intravenous induction and subcutaneous maintenance thera…
https://buff.ly/1VjZIYp
Jul-19-2025
